Table 4.3

Main adverse reactions of AED, which may be serious and sometimes life-threatening

AEDMain adverse reactionsSerious and sometimes life threatening reactions35,37
CarbamazepineIdiosyncratic (rash)*, sedation, headache, ataxia, nystagmus, diplopia, tremor, impotence, hyponatraemia, cardiac arrhythmiaStevens-Johnson syndrome, AHS, hepatic failure, haematological
ClobazamSevere sedation, fatigue, drowsiness, behavioural and cognitive impairment, restlessness, aggressiveness, hypersalivation and coordination disturbances. Tolerance and withdrawal syndromeNo
ClonazepamAs of clobazamNo
EthosuximideIdiosyncratic (rash)*, gastro-intestinal disturbances, anorexia, weight loss, drowsiness, photophobia and headacheStevens-Johnson syndrome, AHS, renal and hepatic failure, haematological
GabapentinWeight gain,** peripheral oedema, behavioural changesNo
LamotrigineIdiosyncratic (rash)*, tics, insomnia, dizziness, diplopia, headache, ataxia, astheniaStevens-Johnson syndrome, AHS, hepatic failure
LevetiracetamIrritability, behavioural changes, insomnia, asthenia, dizziness.No
OxcarbazepineIdiosyncratic (rash)*, headache, dizziness, weakness, nausea, somnolence, ataxia and diplopia, hyponatraemiaAHS, haematological
PhenobarbitoneIdiosyncratic (rash)*, severe drowsiness, sedation, impairment of cognition and concentration, hyperkinesia and agitation in children, shoulder-hand syndromeStevens-Johnson syndrome, AHS, haematological
PhenytoinIdiosyncratic (rash)*, ataxia, drowsiness, lethargy, sedation, encephalopathy, gingival hyperplasia, hirsutism, dysmorphism, rickets, osteomalaciaStevens-Johnson syndrome, AHS, renal and hepatic failure, haematological
TiagabineStupor or spike-wave stupor, weaknessNo
TopiramateSomnolence, anorexia, fatigue, nervousness, difficulty with concentration/attention, memory impairment, psychomotor slowing, metabolic acidosis, weight loss,** language dysfunction, renal calculi, acute angle-closure glaucoma and other ocular abnormalities, paraesthesiaHepatic failure, anhidrosis***
ValproateNausea, vomiting, dyspepsia, weight gain,** tremor, hair loss, hormonal in women.Hepatic and pancreatic failure
VigabatrinFatigue, drowsiness, weight gain,** behavioural changesIrreversible visual field defects
ZonisamideIdiosyncratic*, drowsiness, anorexia, irritability, photosensitivity, weight loss,** renal calculiStevens-Johnson syndrome, AHS, anhidrosis***

AHS= Anticonvulsant hypersensitivity syndrome which is a potentially fatal but rare reaction, manifests as rash, fever, tender lymphadenopathy, hepatitis, and eosinophilia.42–44 There is usually cross-sensitivity between AEDs, which have the potential to cause AHS; these AEDs should be avoided in patients who have developed idiosyncratic reactions to one or another drug.

*

The appearance of skin rash mandates immediate discontinuation of the responsible agent because it may progress to Stevens-Johnson syndrome and anticonvulsant hypersensitive syndrome.

**

The risks of obesity are emphasised routinely in the media in the United States and other industrialized countries where obesity has become epidemic. Patients and particularly women should be informed of AEDs that are likely to cause weight gain (gabapentin, pregabalin, valproate and vigabatrin). Conversely, topiramate and zonisamide may cause significant weight loss, which can be relentless. Lamotrigine, levetiracetam and phenytoin are weight neutral AEDs. 45

***

Hypohidrosis (in most cases anhidrosis=inability to sweat) is a rare but serious adverse effect of topiramate and zonisamide probably due to a reduction in carbonic anhydrase isoenzymes II and IV. Children particularly in warm environments are at higher risk.46–48

From: Chapter 4, Principles of Therapy in Epilepsies

Cover of The Epilepsies
The Epilepsies: Seizures, Syndromes and Management.
Panayiotopoulos CP.
Oxfordshire (UK): Bladon Medical Publishing; 2005.
Copyright © 2005, Bladon Medical Publishing, an imprint of Springer Science+Business Media.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.